Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Support Our Content
    eNewsletter
    Donate
  • Jefferson Adams
    Jefferson Adams

    Celiac Disease Treatment TIMP-GLIA Wins Fast Track Status

    Reviewed and edited by a celiac disease expert.

    TIMP-GLIA is a new nanoparticle-based celiac disease treatment. Will it work? The FDA has granted Fast track status to maker Cour Pharmaceuticals, so we may know sooner rather than later.

    Celiac Disease Treatment TIMP-GLIA Wins Fast Track Status - Photo: CC--Alosh Bennett
    Caption: Photo: CC--Alosh Bennett

    Celiac.com 02/05/2018 - TIMP-GLIA, a new nanoparticle-based celiac disease treatment currently under development by Cour Pharmaceuticals, has received Fast Track Designation from the US Food and Drug Administration (FDA). Phase 1 studies to assess the safety and tolerability of TIMP-GLIA are currently underway in the United States.

    TIMP-GLIA works in part by encapsulating a component of wheat within a nanoparticle. The treatment has resulted in gluten tolerance in numerous animal models. By encasing components of gluten proteins in a nanoparticle, Cour is hoping that the gluten will remain unrecognized by the body's immune system, at least until immune tolerance can be generated through non-inflammatory antigen presentation.

    Celiac.com Sponsor (A12):
    The FDA created the fast track process to speed development, review and commercialization of drugs that target serious conditions and fill an unmet medical need. Fast Track Designation puts Cour in a "prime position to advance an innovative new approach for the treatment of Celiac Disease," said John J. Puisis, CEO of Cour Pharmaceuticals.

    Cour is investigating TIMP-GLIA as part of an effort to reprogram the body's immune system so patients develop a tolerance to gluten as a non-threatening substance and ultimately to reduce or reverse celiac disease without the need for immune suppressing drugs. Cour's approach is designed to work by encasing a component of wheat in a nanoparticle, and introducing that particle into a celiac disease patient. If it works as designed, the gluten will remain unrecognized by the body's immune system until tolerance can be achieved through non-inflammatory antigen presentation.

    The phase 1 clinical trial for TIMP-GLIA study is being conducted at centers in the United States. The objective of the study is to assess the safety and tolerability of TIMP-GLIA when administered intravenously (IV) as a single dose at ascending dose levels and as a repeat dose in subjects with celiac disease.

    All in all, this is another of many bold and encouraging efforts to treat or cure celiac disease that have arisen in the last few years. Look for news of success or failure over then next few years.

    Source: Pharmabiz.com



    User Feedback

    Recommended Comments

    Guest Laura

    Please ask yourself one question; Why are scientists trying to alter the human body rather than correcting the root cause of the problem which is modern dwarf wheat? There are studies showing that individuals with neither celiac disease nor diagnosed gluten sensitivity have "adverse reactions" to gluten. Diseases such as irritable bowel syndrome, fibromyalgia and other inflammatory diseases are believed to be worsened by exposure to gluten. Could it be that gastrointestinal diseases overall are perpetuated by the wheat proteins?

    Link to comment
    Share on other sites
    Guest T. Adams

    Posted

    I do NOT trust any Pharmaceuticals to make anything "safe", all they care about is making money. Just take the time to read the "possible" side effects on any thing they make. Nor do I trust the FDA.

    Link to comment
    Share on other sites
    Guest Scott Adams

    Posted

    I do NOT trust any Pharmaceuticals to make anything "safe", all they care about is making money. Just take the time to read the "possible" side effects on any thing they make. Nor do I trust the FDA.

    This may not be for everyone...there is, after all, always the gluten-free diet for life.

    Link to comment
    Share on other sites
    Guest Jefferson

    Posted

    I do NOT trust any Pharmaceuticals to make anything "safe", all they care about is making money. Just take the time to read the "possible" side effects on any thing they make. Nor do I trust the FDA.

    The list of safe and effective products made by pharmaceutical companies is likely long enough to fill a library. If you were born in the 20th century, you are likely alive and disease free precisely due to pharma products like vaccines. I don't know about you, but I'm pretty happy no having polio or measles, mumps, rubella, diphtheria, or any number of other potentially deadly or debilitating diseases that have been prevented by vaccines. So, there's that.

    Link to comment
    Share on other sites


    Create an account or sign in to comment

    You need to be a member in order to leave a comment

    Create an account

    Sign up for a new account in our community. It's easy!

    Register a new account

    Sign in

    Already have an account? Sign in here.

    Sign In Now

  • Get Celiac.com Updates:
    Support Celiac.com:
    Donate
  • About Me

    Jefferson Adams

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University. His articles, essays, poems, stories and book reviews have appeared in numerous magazines, journals, and websites, including North American Project, Antioch Review, Caliban, Mississippi Review, Slate, and more. He is the author of more than 2,500 articles on celiac disease. His university coursework includes studies in science, scientific methodology, biology, anatomy, physiology, medicine, logic, and advanced research. He previously devised health and medical content for Colgate, Dove, Pfizer, Sharecare, Walgreens, and more. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of numerous books, including "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

    >VIEW ALL ARTICLES BY JEFFERSON ADAMS

     


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Jefferson Adams
    Is Effective Enzyme Therapy for Celiac Disease Just Around The Corner?
    Celiac.com 09/25/2017 - There are currently several efforts underway to develop successful commercial enzyme treatments for celiac disease. Efforts include looking at the digestive enzymes in plants, such as the papaya and star fruits, including such predatory plants, such as the pitcher plant.
    One focus has been on developing enzymes that can break down gluten before it can trigger an immune reaction. This could prove helpful to many people with celiac disease.
    One such enzyme under development is Latiglutenase, formerly known as ALV003. Latiglutenase is a new name for an enzyme therapy designed to be taken with meals.
    The idea is that a person with celiac disease would take an enzyme tablet with a meal. If the meal had mild gluten contamination, the enzyme’s two recombinant p...


    Jefferson Adams
    Will a New Enzyme Mean No More Gluten-Free Diet for Celiac Disease?
    Will a new treatment enable people with celiac disease to ditch a gluten-free diet?
    About one in a hundred people in the United States is affected by celiac disease. If you're one of them, you know how hard it can be to maintain a strict gluten-free diet.
    Everyone's got their horror stories about trying to simply eat a meal, only to have a tiny amount of gluten wreck havoc on their digestive system.
    There are currently no therapeutics on the market to treat celiac disease, says Sydney Gordon, a scientist at Ab Initio Biotherapeutics. Sure, there are other over-the-counter enzyme treatments, Gordon adds, but most are slow to act, or don't break down enough gluten to prevent a reaction.
    "There are no other enzymes on the market for celiac disease," said Justin Siegel, the co...


    Jefferson Adams
    Investors Bet Big on Vaccine Therapy for Celiac Disease
    Celiac.com 12/22/2017 - Venture capital firms Arch Venture, and Vatera are betting big on biotech startup ImmusanT, the makers of potential celiac disease vaccine Nexvax2.
    Arch and Vatera have funded a $40 million B round that will support ImmusanT's development of their celiac treatment through Phase II testing. Full data are expected in mid-2019.
    As part of it's efforts, Arch Venture partner and former head of research at Celgene, Tom Daniel, will join the board at ImmusanT. Additionally, renowned immunologist and Arch managing director Steven Gillis will also join the board at ImmusanT.
    Nexvax2 is the first prong in ImmusanT's efforts to develop a treatment that creates immune system tolerance to thwart autoimmune diseases. If they are successful in tackling celiac disease...


    Jefferson Adams
    Escalating Doses of Nexvax2 Avoids Adverse Symptoms, Raises Patient Tolerance
    Celiac.com 01/04/2018 - Nexvax2 is a peptide-based, epitope-specific immunotherapy intended to reduce reactions to natural gluten exposure, and ultimately restore tolerance to gluten in patients with celiac disease.
    Celiac disease patients who received fixed intradermal doses of Nexvax2 lost their sensitivity to the HLA-DQ2·5-restricted gluten epitopes in Nexvax2, but their tolerance was limited to 150 μg, due to gastrointestinal symptoms and cytokine release, mimicking gluten exposure, that accompany the first dose.
    A team of researchers recently set out to test whether small doses in steps might reduce the first dose effect of Nexvax2 in celiac disease patients.
    The research team included James M. Daveson, Hooi C. E, Jane M. Andrews, Timothy King, Kaela E. Goldstein, John L...


  • Recent Activity

    1. - Barcino replied to Barcino's topic in Post Diagnosis, Recovery & Treatment of Celiac Disease
      1

      Antibodies went up

    2. - Scott Adams replied to jjiillee's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      9

      Daughter waiting for appointment

    3. - Barcino posted a topic in Post Diagnosis, Recovery & Treatment of Celiac Disease
      1

      Antibodies went up

    4. - jjiillee replied to jjiillee's topic in Celiac Disease Pre-Diagnosis, Testing & Symptoms
      9

      Daughter waiting for appointment

    5. - BoiseNic replied to BoiseNic's topic in Dermatitis Herpetiformis
      7

      Skinesa


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      126,310
    • Most Online (within 30 mins)
      7,748

    KristaS
    Newest Member
    KristaS
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.9k
    • Total Posts
      69.3k

  • Celiac.com Sponsor (A22):





  • Celiac.com Sponsor (A21):



  • Popular Now

    • Ems10
      7
    • Celiacsugh
    • BoiseNic
      7
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...